Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1489-1490. doi: 10.1164/rccm.201705-0995LE.

Frank van Leth^{1

2}, Gunar Günther^{3

4

5}, Harald Hoffmann^{6

7}, Christoph Lange^{3

4

8

9}; European MDR-TB Database Collaboration

European MDR-TB Database Collaboration:
Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Mathilde Fréchet-Jachym, Gina Gualano, Lorenzo Guglielmetti, Gunar Günther, Harald Hoffmann, Jan Heyckendorf, Barbara Kalsdorf, Heinke Kunst, Christoph Lange, Wiel de Lange, Damien Le Dû, Vaira Leimane, Frank van Leth, Rita Macedo, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Ioana D Olaru, Olena Oliveira, Veronika Polcová, Emanuele Pontali, Cristina Popa, Jérôme Robert, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Nicolas Veziris, Piret Viiklepp

¹ 1 University of Amsterdam Amsterdam, the Netherlands.
² 2 Amsterdam Institute for Global Health and Development Amsterdam, the Netherlands.
³ 3 Research Center Borstel Borstel, Germany.
⁴ 4 German Center for Infection Research (DZIF) Borstel, Germany.
⁵ 5 University of Namibia, School of Medicine Windhoek, Namibia.
⁶ 6 SYNLAB Gauting, SYNLAB Humane Genetic Munich-Gauting, Germany.
⁷ 7 Institute of Microbiology & Laboratory Medicine, Dpt IML red; WHO Supranational Reference Laboratory of Tuberculosis Munich-Gauting, Germany.
⁸ 8 University of Lübeck Lübeck, Germany and.
⁹ 9 Karolinska Institute Stockholm, Sweden.

No abstract available

Publication types